Indeed, the targeted chemotherapeutic drug for leukemia, imatinib, has been shown to enhance anti-tumor immunity by activating cytotoxic T cells and suppressing Tregs in an IDO1-dependent manner [201]. This evidence concerns the gene IDO1 and neoplasm.